{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:19:11Z","timestamp":1793089151013,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0296"],"award-info":[{"award-number":["W81XWH-21-1-0296"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA212007"],"award-info":[{"award-number":["U01CA212007"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA231776"],"award-info":[{"award-number":["U01CA231776"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA273956"],"award-info":[{"award-number":["U54CA273956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semradonc.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:29:37Z","timestamp":1686940177000},"page":"232-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology"],"prefix":"10.1016","volume":"33","author":[{"given":"Philip","family":"Sutera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bergom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.semradonc.2023.03.001_bib0001","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.semradonc.2023.03.001_bib0002","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.semradonc.2023.03.001_bib0003","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.semradonc.2023.03.001_bib0004","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0005","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B-cell non-hodgkin's lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5732\/cjc.012.10216","article-title":"Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer","volume":"31","author":"Guan","year":"2012","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.12659\/PJR.890745","article-title":"Applications of linac-mounted kilovoltage cone-beam computed tomography in modern radiation therapy: A review","volume":"79","author":"Srinivasan","year":"2014","journal-title":"Pol J Radiol"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.meddos.2020.11.002","article-title":"Comparative evaluation of treatment plan quality for a prototype biology-guided radiotherapy system in the treatment of nasopharyngeal carcinoma","volume":"46","author":"Han","year":"2021","journal-title":"Med Dosim"},{"issue":"9","key":"10.1016\/j.semradonc.2023.03.001_bib0009","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/j.clon.2022.03.022","article-title":"Prostate Volume Changes during Extreme and Moderately Hypofractionated Magnetic Resonance Image-guided Radiotherapy","volume":"34","author":"Alexander","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ac5ad2","article-title":"Automated scripting of the dosimetric evaluation of adaptive versus non-adaptive radiotherapy","volume":"8","author":"Samant","year":"2022","journal-title":"Biomed Phys Eng Express"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ijrobp.2021.09.053","article-title":"Comparative effectiveness analysis of 3D-conformal radiation therapy versus intensity modulated radiation therapy (IMRT) in a prospective multicenter cohort of patients with breast cancer","volume":"112","author":"Jagsi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.semradonc.2023.03.001_bib0012","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/odi.13599","article-title":"IMRT versus 2D\/3D conformal RT in oropharyngeal cancer: A review of the literature and meta-analysis","volume":"27","author":"Alterio","year":"2021","journal-title":"Oral Dis"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10147-016-1057-y","article-title":"A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer","volume":"22","author":"Shimizuguchi","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.radonc.2009.08.011","article-title":"Volumetric modulated arc therapy (VMAT) vs serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer","volume":"93","author":"Wolff","year":"2009","journal-title":"Radiother Oncol"},{"issue":"16","key":"10.1016\/j.semradonc.2023.03.001_bib0015","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1158\/0008-5472.CAN-05-0656","article-title":"Prediction of radiation sensitivity using a gene expression classifier","volume":"65","author":"Torres-Roca","year":"2005","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.semradonc.2023.03.001_bib0016","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): A cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.semradonc.2023.03.001_bib0017","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.semradonc.2023.03.001_bib0018","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"issue":"27","key":"10.1016\/j.semradonc.2023.03.001_bib0020","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"6871","key":"10.1016\/j.semradonc.2023.03.001_bib0021","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0022","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.semradonc.2023.03.001_bib0023","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.semradonc.2023.03.001_bib0024","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.3390\/cancers13236103","article-title":"Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS)","volume":"13","author":"W\u00e4rnberg","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"32","key":"10.1016\/j.semradonc.2023.03.001_bib0025","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial","volume":"32","author":"W\u00e4rnberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0026","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2022.06.072","article-title":"A novel biosignature identifies patients with DCIS with high risk of local recurrence after breast conserving surgery and radiation therapy","volume":"115","author":"Vicini","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijrobp.2022.07.2311","article-title":"The Elusive Prize of Radiation Therapy Predictive Assays in Breast Cancer","volume":"115","author":"Woodward","year":"2023","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0028","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.semradonc.2023.03.001_bib0029","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N E J Med"},{"issue":"25","key":"10.1016\/j.semradonc.2023.03.001_bib0030","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0031","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-008-0130-2","article-title":"The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study","volume":"116","author":"Mook","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0032","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-008-0191-2","article-title":"Validation of 70-gene prognosis signature in node-negative breast cancer","volume":"117","author":"Bueno-de-Mesquita","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.semradonc.2023.03.001_bib0033","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Eng J Med"},{"issue":"8","key":"10.1016\/j.semradonc.2023.03.001_bib0034","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.semradonc.2023.03.001_bib0035","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.semradonc.2023.03.001_bib0036","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.semradonc.2023.03.001_bib0037","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","article-title":"Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy","volume":"29","author":"Arvold","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.suronc.2013.10.001","article-title":"Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis","volume":"22","author":"Wang","year":"2013","journal-title":"Surg Oncol"},{"issue":"15 Pt 1","key":"10.1016\/j.semradonc.2023.03.001_bib0039","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.semradonc.2023.03.001_bib0040","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.semradonc.2023.03.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA501","article-title":"LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal a breast cancer (BC)","volume":"40","author":"Whelan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.semradonc.2023.03.001_bib0042","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0043","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): A randomised controlled trial","volume":"16","author":"Kunkler","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0044","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2022.06.013","article-title":"21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age \u2265 70 with T1N0 ER\/PR\u00a0+\u00a0HER2- breast cancer treated with breast conserving surgery and endocrine therapy","volume":"174","author":"Chevli","year":"2022","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4048\/jbc.2020.23.e36","article-title":"Impact of oncotype DX recurrence score on the patterns of locoregional recurrence in breast cancer (Korean Radiation Oncology Group 19-06)","volume":"23","author":"Kim","year":"2020","journal-title":"J Breast Cancer"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0046","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20","volume":"28","author":"Mamounas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.semradonc.2023.03.001_bib0047","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199710023371402","article-title":"Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer","volume":"337","author":"Ragaz","year":"1997","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.semradonc.2023.03.001_bib0048","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM199710023371401","article-title":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial","volume":"337","author":"Overgaard","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0049","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/0284186X.2017.1401735","article-title":"Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials","volume":"57","author":"Laurberg","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0050","doi-asserted-by":"crossref","unstructured":"Mamounas EP, Liu Q, Paik S, et al: 21-gene recurrence score and locoregional recurrence in node-positive\/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst 109(4):1-8, 2017","DOI":"10.1093\/jnci\/djw259"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0051","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2019.5559","article-title":"Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer","volume":"6","author":"Woodward","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0052","article-title":"Genomically guided breast radiation therapy: A review of the current data and future directions","volume":"6","author":"Liveringhouse","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"35","key":"10.1016\/j.semradonc.2023.03.001_bib0053","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.19.00761","article-title":"Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer","volume":"37","author":"Sj\u00f6str\u00f6m","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.semradonc.2023.03.001_bib0054","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-14-2898","article-title":"Development and validation of a novel radiosensitivity signature in human breast cancer","volume":"21","author":"Speers","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.semradonc.2023.03.001_bib0055","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/1078-0432.CCR-18-0825","article-title":"Integrating radiosensitivity and immune gene signatures for predicting benefit of radiotherapy in breast cancer","volume":"24","author":"Cui","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0056","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/annonc\/mdu090","article-title":"Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy","volume":"25","author":"Bane","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0057","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0058","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijrobp.2020.08.038","article-title":"Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity","volume":"109","author":"Lalani","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0059","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0060","doi-asserted-by":"crossref","first-page":"e66855","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0061","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0062","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0063","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0064","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0065","first-page":"1","article-title":"Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer","volume":"2","author":"Hu","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0066","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0067","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0068","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0069","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","article-title":"A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy","volume":"67","author":"Klein","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0070","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.eururo.2017.05.009","article-title":"Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens","volume":"72","author":"Nguyen","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0071","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41391-020-0226-2","article-title":"Performance of clinicopathologic models in men with high risk localized prostate cancer: Impact of a 22-gene genomic classifier","volume":"23","author":"Tosoian","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0072","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijrobp.2018.08.030","article-title":"Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy","volume":"103","author":"Berlin","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0073","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/pcan.2016.58","article-title":"Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer","volume":"20","author":"Nguyen","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0074","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0075","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2023.03.001_bib0076","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.semradonc.2023.03.001_bib0077","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial","volume":"296","author":"Thompson","year":"2006","journal-title":"Jama"},{"issue":"9858","key":"10.1016\/j.semradonc.2023.03.001_bib0078","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.semradonc.2023.03.001_bib0079","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95","volume":"27","author":"Wiegel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2023.03.001_bib0080","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","article-title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: A matched, retrospective analysis","volume":"17","author":"Zhao","year":"2016","journal-title":"lancet Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0081","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41391-019-0185-7","article-title":"Prospective study to define the clinical utility and benefit of decipher testing in men following prostatectomy","volume":"23","author":"Marascio","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0082","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.prro.2019.09.016","article-title":"Clinical utility of a genomic classifier in men undergoing radical prostatectomy: The PRO-IMPACT trial","volume":"10","author":"Gore","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0083","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.30665","article-title":"Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study","volume":"123","author":"Gore","year":"2017","journal-title":"Cancer"},{"issue":"10260","key":"10.1016\/j.semradonc.2023.03.001_bib0084","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0086","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.semradonc.2023.03.001_bib0087","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0088","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG\/RTOG 9601 Randomized Clinical Trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0089","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0091","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ijrobp.2018.08.052","article-title":"Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: The NRG Oncology\/RTOG 0534 SPPORT trial","volume":"102","author":"Pollack","year":"2018","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0092","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: The SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2023.03.001_bib0093","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2023.03.001_bib0094","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"26","key":"10.1016\/j.semradonc.2023.03.001_bib0095","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0096","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.03.001_bib0097","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0098","doi-asserted-by":"crossref","first-page":"20406","DOI":"10.1038\/s41598-020-77259-9","article-title":"A novel methylation signature predicts radiotherapy sensitivity in glioma","volume":"10","author":"Feng","year":"2020","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.semradonc.2023.03.001_bib0099","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1111\/jcmm.15145","article-title":"Gene signatures based on therapy responsiveness provide guidance for combined radiotherapy and chemotherapy for lower grade glioma","volume":"24","author":"Li","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.semradonc.2023.03.001_bib0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: The current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"24","key":"10.1016\/j.semradonc.2023.03.001_bib0101","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.20.02730","article-title":"Children's oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.semradonc.2023.03.001_bib0102","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9538","key":"10.1016\/j.semradonc.2023.03.001_bib0103","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0104","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ctrv.2015.10.001","article-title":"Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives","volume":"41","author":"Mirghani","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0105","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1158\/0008-5472.CAN-13-0587","article-title":"Enhanced radiation sensitivity in HPV-positive head and neck cancer","volume":"73","author":"Kimple","year":"2013","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0106","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1073\/pnas.95.5.2290","article-title":"Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways","volume":"95","author":"Song","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0107","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.radonc.2013.03.013","article-title":"HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity","volume":"107","author":"Rieckmann","year":"2013","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0108","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","article-title":"Human papillomavirus testing in head and neck carcinomas: Guideline from the college of American pathologists","volume":"142","author":"Lewis","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0109","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/0008-5472.CAN-13-2479","article-title":"p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors","volume":"74","author":"Dok","year":"2014","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1158\/0008-5472.CAN-21-2101","article-title":"p16 represses DNA damage repair via a novel ubiquitin-dependent signaling cascade","volume":"82","author":"Molkentine","year":"2022","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.semradonc.2023.03.001_bib0111","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/onc.2016.250","article-title":"TRIP12 as a mediator of human papillomavirus\/p16-related radiation enhancement effects","volume":"36","author":"Wang","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.semradonc.2023.03.001_bib0112","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10166","key":"10.1016\/j.semradonc.2023.03.001_bib0113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"10166","key":"10.1016\/j.semradonc.2023.03.001_bib0114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0115","first-page":"S1168","article-title":"LBA38 pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 \u201cpembroRad\u201d randomized trial","volume":"31","author":"Bourhis","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0116","series-title":"Safety of Radiotherapy With Concurrent and Adjuvant MEDI4736 (Durvalumab) in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin: NRG-HN004","author":"Mell","year":"2019"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0117","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN cancer research group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.semradonc.2023.03.001_bib0118","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0119","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","article-title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial","volume":"20","author":"Nichols","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0120","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.30570","article-title":"TRAF3\/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma","volume":"123","author":"Hajek","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0121","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1038\/s41467-021-26570-8","article-title":"Inhibition of histone acetyltransferase function radiosensitizes CREBBP\/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function","volume":"12","author":"Kumar","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.semradonc.2023.03.001_bib0122","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41556-018-0260-7","article-title":"An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy","volume":"21","author":"Liu","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"18","key":"10.1016\/j.semradonc.2023.03.001_bib0123","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-15-2785","article-title":"Proteomic profiling identifies PTK2\/FAK as a driver of radioresistance in HPV-negative head and neck cancer","volume":"22","author":"Skinner","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0124","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-11-2260","article-title":"TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence","volume":"18","author":"Skinner","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.semradonc.2023.03.001_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.139837","article-title":"Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis","volume":"5","author":"Uzunparmak","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.semradonc.2023.03.001_bib0126","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/1078-0432.CCR-18-0776","article-title":"A five-MicroRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV infection","volume":"25","author":"Hess","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.semradonc.2023.03.001_bib0127","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","article-title":"Integrative analysis identifies a Novel AXL-PI3 Kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer","volume":"23","author":"Skinner","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.001_bib0128","doi-asserted-by":"crossref","unstructured":"Abdelhakiem M, Bao R, Pifer PM, et al. Th2 cells are associated with recurrence following radiation in human papillomavirus negative head and neck cancer. 2022.","DOI":"10.21203\/rs.3.rs-1537302\/v1"},{"issue":"1","key":"10.1016\/j.semradonc.2023.03.001_bib0129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.124762","article-title":"Variations in HPV function are associated with survival in squamous cell carcinoma","volume":"4","author":"Gleber-Netto","year":"2019","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.semradonc.2023.03.001_bib0130","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.semradonc.2023.03.001_bib0131","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:16:58Z","timestamp":1762355818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429623000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1053429623000152"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.03.001","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}